Active, not recruitingPHASE1, PHASE2NCT03277729
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Studying Diffuse large B-cell lymphoma of the central nervous system
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Mazyar Shadman, MD,MPHFred Hutch/University of Washington Cancer Consortium
- Intervention
- Chimeric Antigen Receptor T-Cell Therapy(biological)
- Enrollment
- 53 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2039
Study locations (1)
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
Mustang Bio
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03277729 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma of the central nervous system
Additional recruiting or active studies for the same condition.
See all trials for Diffuse large B-cell lymphoma of the central nervous system →